TNSN06430A1 - Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases - Google Patents
Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseasesInfo
- Publication number
- TNSN06430A1 TNSN06430A1 TNP2006000430A TNSN06430A TNSN06430A1 TN SN06430 A1 TNSN06430 A1 TN SN06430A1 TN P2006000430 A TNP2006000430 A TN P2006000430A TN SN06430 A TNSN06430 A TN SN06430A TN SN06430 A1 TNSN06430 A1 TN SN06430A1
- Authority
- TN
- Tunisia
- Prior art keywords
- treatment
- inflammatory
- useful
- diseases
- compositions
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000011963 CXCR3 Receptors Human genes 0.000 title 1
- 108010061300 CXCR3 Receptors Proteins 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004957 immunoregulator effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58390104P | 2004-06-28 | 2004-06-28 | |
| PCT/US2005/023251 WO2006004915A1 (en) | 2004-06-28 | 2005-06-28 | Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN06430A1 true TNSN06430A1 (en) | 2008-02-22 |
Family
ID=35197976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2006000430A TNSN06430A1 (en) | 2004-06-28 | 2006-12-26 | Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7939538B2 (enExample) |
| EP (1) | EP1771447A1 (enExample) |
| JP (1) | JP2008504301A (enExample) |
| KR (1) | KR20070045203A (enExample) |
| CN (1) | CN101006088A (enExample) |
| AR (1) | AR049558A1 (enExample) |
| AU (1) | AU2005260620A1 (enExample) |
| BR (1) | BRPI0512703A (enExample) |
| CA (1) | CA2572083A1 (enExample) |
| EA (1) | EA011439B1 (enExample) |
| EC (1) | ECSP077212A (enExample) |
| IL (1) | IL180327A0 (enExample) |
| MA (1) | MA28755B1 (enExample) |
| MX (1) | MX2007000051A (enExample) |
| NO (1) | NO20070484L (enExample) |
| TN (1) | TNSN06430A1 (enExample) |
| TW (1) | TW200611699A (enExample) |
| WO (1) | WO2006004915A1 (enExample) |
| ZA (1) | ZA200700752B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| TW200714610A (en) * | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
| JP2008546843A (ja) * | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| NZ565059A (en) * | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| BRPI0617274A2 (pt) * | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| KR101129868B1 (ko) * | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체 |
| AP2009005053A0 (en) * | 2007-05-03 | 2009-12-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| AU2008251425A1 (en) | 2007-05-10 | 2008-11-20 | Array Biopharma, Inc. | Novel peptide inhibitors of hepatitis C virus replication |
| US20110034487A1 (en) * | 2008-01-22 | 2011-02-10 | Amgen Inc. | Cxcr3 antagonists |
| CA2720729A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2483290A4 (en) * | 2009-09-28 | 2013-05-01 | Intermune Inc | CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS |
| EP2597095A4 (en) * | 2010-07-23 | 2014-10-01 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND AND ITS USE |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| EP2935246B1 (en) | 2012-12-21 | 2018-07-25 | Gilead Calistoga LLC | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| PL3008053T3 (pl) | 2013-06-14 | 2018-08-31 | Gilead Calistoga Llc | Inhibitory 3-kinazy fosfatydyloinozytolu |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| WO1998026664A1 (en) | 1996-12-17 | 1998-06-25 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| FR2778662B1 (fr) | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1216232B1 (en) | 1999-08-27 | 2006-10-11 | ChemoCentryx Inc | Heterocyclic compounds and methods for modulating cxcr3 function |
| CA2385736C (en) * | 1999-09-16 | 2011-11-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| EP1686120A3 (en) | 1999-10-27 | 2007-05-30 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| AU2001297717B2 (en) | 2000-12-11 | 2006-02-23 | Amgen Inc. | CXCR3 antagonists |
| ITMI20010808A1 (it) | 2001-04-13 | 2002-10-13 | Ilpea Ind Spa | Procedimento per ottenere una pelle sintetica adatta in particolare arivestire plance portastrumenti in autoveicoli e pelle cosi' ottenuta |
| US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| ATE507210T1 (de) | 2002-03-07 | 2011-05-15 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| CN100491358C (zh) | 2002-05-09 | 2009-05-27 | 赛特凯恩蒂克公司 | 嘧啶酮类化合物、组合物及方法 |
| JP2005536475A (ja) * | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| US20040242498A1 (en) | 2003-02-27 | 2004-12-02 | Collins Tassie L. | CXCR3 antagonists |
| US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| US7375102B2 (en) * | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| WO2006023381A1 (en) | 2004-08-16 | 2006-03-02 | Taigen Biotechnology | Pyrimidinone compounds |
| JP2008546843A (ja) | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
-
2005
- 2005-06-27 US US11/168,005 patent/US7939538B2/en not_active Expired - Fee Related
- 2005-06-28 AU AU2005260620A patent/AU2005260620A1/en not_active Abandoned
- 2005-06-28 KR KR1020077002012A patent/KR20070045203A/ko not_active Withdrawn
- 2005-06-28 CA CA002572083A patent/CA2572083A1/en not_active Abandoned
- 2005-06-28 JP JP2007518379A patent/JP2008504301A/ja active Pending
- 2005-06-28 EP EP05789126A patent/EP1771447A1/en not_active Withdrawn
- 2005-06-28 WO PCT/US2005/023251 patent/WO2006004915A1/en not_active Ceased
- 2005-06-28 MX MX2007000051A patent/MX2007000051A/es not_active Application Discontinuation
- 2005-06-28 ZA ZA200700752A patent/ZA200700752B/xx unknown
- 2005-06-28 BR BRPI0512703-3A patent/BRPI0512703A/pt not_active IP Right Cessation
- 2005-06-28 CN CNA2005800277780A patent/CN101006088A/zh active Pending
- 2005-06-28 TW TW094121708A patent/TW200611699A/zh unknown
- 2005-06-28 EA EA200700169A patent/EA011439B1/ru not_active IP Right Cessation
- 2005-06-28 AR ARP050102670A patent/AR049558A1/es not_active Application Discontinuation
-
2006
- 2006-12-25 IL IL180327A patent/IL180327A0/en unknown
- 2006-12-26 TN TNP2006000430A patent/TNSN06430A1/en unknown
-
2007
- 2007-01-25 NO NO20070484A patent/NO20070484L/no not_active Application Discontinuation
- 2007-01-29 EC EC2007007212A patent/ECSP077212A/es unknown
- 2007-01-29 MA MA29639A patent/MA28755B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200700169A1 (ru) | 2007-08-31 |
| ECSP077212A (es) | 2007-03-29 |
| EP1771447A1 (en) | 2007-04-11 |
| US20060069099A1 (en) | 2006-03-30 |
| NO20070484L (no) | 2007-03-26 |
| AR049558A1 (es) | 2006-08-16 |
| KR20070045203A (ko) | 2007-05-02 |
| MX2007000051A (es) | 2007-05-11 |
| CA2572083A1 (en) | 2006-01-12 |
| IL180327A0 (en) | 2007-07-04 |
| CN101006088A (zh) | 2007-07-25 |
| US7939538B2 (en) | 2011-05-10 |
| EA011439B1 (ru) | 2009-02-27 |
| WO2006004915A1 (en) | 2006-01-12 |
| JP2008504301A (ja) | 2008-02-14 |
| TW200611699A (en) | 2006-04-16 |
| MA28755B1 (fr) | 2007-07-02 |
| AU2005260620A1 (en) | 2006-01-12 |
| ZA200700752B (en) | 2008-09-25 |
| BRPI0512703A (pt) | 2008-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN06430A1 (en) | Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases | |
| MX2007000044A (es) | Compuestos, composiciones y metodos de tetrahidroquinazolin-4(3h)- ona-relacionados y tetrahidropirido [2,3-d] pirimidin-4(3h)-ona- relacionados para su uso. | |
| WO2007002701A3 (en) | Anti-inflammatory aryl nitrile compounds | |
| IL163629A0 (en) | Glutaminyl derivatives and pharmaceutical compositions containing the same | |
| WO2007100610A3 (en) | Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators | |
| WO2005060665A8 (en) | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | |
| WO2006119504A3 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
| EA200300663A1 (ru) | Антагонисты cxcr3 | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| NZ610633A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| MX2010007023A (es) | Agonistas del receptor glucocorticoide sustituido de c20-c21. | |
| CA2620129C (en) | Diaminopyrimidines as p2x3 and p2x2/3 modulators | |
| GB0510584D0 (en) | Organic compounds | |
| IS8056A (is) | Bensoxasínýl-amídósýklópentýl-heterósýklýskir stillar á flakkboða viðtaka | |
| TW200630374A (en) | Thiazolyldihydroindazoles | |
| TW200624432A (en) | Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto | |
| WO2007064553A3 (en) | Thiazole derivatives as cxcr3 receptor modulators | |
| MA29561B1 (fr) | DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE | |
| WO2007070433A3 (en) | 2-arylthiazole derivatives as cxcr3 receptor modulators | |
| TW200612964A (en) | Methods for preparing p2x7 inhibitors | |
| WO2004075863A3 (en) | Cxcr3 antagonists | |
| IL174678A0 (en) | Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist | |
| WO2006004924A3 (en) | Imidazolo-related compounds, compositions and methods for their use | |
| ATE430761T1 (de) | Vla-4-antagonisten | |
| UA81464C2 (en) | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS |